Clopidogrel Bisulfate
Product Images NDC 68151-3118

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 68151-3118). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

A horizontal bar chart titled 'Effect on active metabolite AUC Mean and 90% confidence interval' showing the influence of co-administered proton pump inhibitors (PPIs) on active metabolite levels. The chart lists four PPIs with doses: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. Each has a black square marker with horizontal error bars indicating the mean and 90% confidence intervals on a scale ranging approximately from 0.4 to 1.4 on the x-axis.*

FDA Label Image

Figure2 (Figure2)

A line chart showing cumulative event rates over 12 months of follow-up comparing Clopidogrel (+ aspirin) and placebo (+ aspirin). The x-axis represents months of follow-up, and the y-axis represents the cumulative event rate in percentage. Clopidogrel (+ aspirin) shows a lower cumulative event rate compared to placebo (+ aspirin) throughout the follow-up period.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart illustrating hazard ratios with 95% confidence intervals, comparing Clopidogrel versus placebo across various baseline characteristics and concomitant medication therapies. It includes data categories such as diagnosis, age, gender, race, cardiac enzymes, diabetes status, previous myocardial infarction, stroke, and use of medications like aspirin, beta-blockers, ACE inhibitors, and lipid-lowering agents.*

FDA Label Image

Figure4 (Figure4)

A Kaplan-Meier survival curve showing the percentage of deaths before first discharge in patients randomized to either placebo or clopidogrel treatment over a 28-day period. The graph includes data points for placebo with 1845 deaths (8.1%) and clopidogrel with 1726 deaths (7.5%), indicating a 7% proportional risk reduction (p=0.03). The x-axis represents days since randomization (up to 28 days) and the y-axis shows the percentage of patients deceased before discharge.*

FDA Label Image

Figure5 (Figure5)

A line chart showing the percentage of patients experiencing death, reinfarction, or stroke before first discharge over 28 days since randomization. Two lines compare placebo and Clopidogrel groups, indicating a lower event rate for Clopidogrel with a 9% proportional risk reduction (p=0.002).*

FDA Label Image

Figure6 (Figure6)

A forest plot comparing event percentages between Clopidogrel bisulfate and placebo groups across various baseline categories, including sex, age, hours since onset, systolic blood pressure, heart rate, fibrinolytic agent use, prognostic index, and Metoprolol allocation. It displays odds ratios with 99% and 95% confidence intervals and includes a global heterogeneity test and proportional reduction statistic.*

FDA Label Image

Figure7 (Figure7)

A forest plot graph comparing Clopidogrel bisulfate and placebo groups across event categories including Killip class, previous myocardial infarction (MI), and infarct location. The graph shows odds ratios with confidence intervals, event percentages for each group, and heterogeneity test results assessing statistical significance.*

FDA Label Image

Figure8 (Figure8)

A line graph showing cumulative event rates of fatal or non-fatal vascular events over a 36-month follow-up period. Two lines compare Aspirin and Clopidogrel, with cumulative event rates (%) on the y-axis and months on the x-axis. The graph indicates a P value of 0.045, suggesting statistical significance.*

FDA Label Image

Label Image (Lbl681513118)

Label of Clopidogrel 75 mg tablet showing the manufacturer as SUN PHARM, lot number JKM6120A, expiration date 08/14, and product NDC code 68151-3118. Also includes a barcode and the designation Rx only.*

FDA Label Image

Structure (Structure)

Chemical structure of clopidogrel bisulfate showing its molecular arrangement, including a thienopyridine core and associated functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.